Search
Formestane
go.drugbank.com/drugs/DB08905ApprovedWithdrawnIt is not US FDA approved, and the intramuscular injection form of formestane (Lentaron) which was approved in Europe has been withdrawn. … It is listed as a prohibited substance by the World Anti-Doping Agency for use in athletes.
Ziprasidone
go.drugbank.com/drugs/DB00246ApprovedInvestigational[A190525] Luckily, several treatment options for psychotic disorders have been introduced to market since the realization of chlorpromazine's antipsychotic properties in 1952. … [A180748] Although ziprasidone is classified as an atypical antipsychotic, it appears to have a lower incidence of metabolic adverse effects compared to other medications in the same class.[A190525]
Tiratricol
go.drugbank.com/drugs/DB03604ApprovedInvestigational[L53383] It was first approved by the EMA on February 12, 2025 for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency,[A274038] a disorder characterized … [A274073] Tiratricol is currently being investigated in US clinical trials.
Beremagene geperpavec
go.drugbank.com/drugs/DB17831ApprovedInvestigationalDeveloped by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB). … [L46916] DEB is caused by mutations in the _COL7A1_ gene that encodes collagen VII (COL7), a major component of the anchoring fibrils for dermal–epidermal cohesion.
Categories: Preparations for Treatment of Wounds and UlcersMifamurtide
go.drugbank.com/drugs/DB13615ApprovedInvestigationalIn the US, it is currently under investigation that holds orphan drug status for the treatment of osteosarcoma [A31746]. … While about 90% of patients with newly diagnosed osteosarcoma may achieve complete remission from first-line therapies, the prognosis is still poor for patients with non-metastatic osteosarcoma with lower
Vibegron
go.drugbank.com/drugs/DB14895ApprovedInvestigationalOn December 23, 2020, vibegron was approved for the same indication in adults. It is available as oral tablets under the market name GEMTESA. … [L28310] Vibegron is the second beta-3 adrenergic agonist approved for the treatment of overactive bladder following [mirabegron], which was approved in 2012.
Categories: Drugs for Urinary Frequency and IncontinenceCyanocobalamin Co-60
go.drugbank.com/drugs/DB09387ApprovedWithdrawnCyanocobalamin Co-60 was used for the diagnosis of pernicious anemia, but now it is withdrawn from the market in the US for unknown reasons.
Medrogestone
go.drugbank.com/drugs/DB09124ApprovedWithdrawnIt was conceived as an alternative for an orally effective contraceptive option.[A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing. … Medrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone.
Edoxudine
go.drugbank.com/drugs/DB13421ApprovedWithdrawn[A32643] It was developed by McNeil Pharmaceutical and approved by Health Canada on December 31, 1992. This medication was later discontinued from the market in 1998.[L1113] … It was later recognized to be effective in vivo in a preclinical model of keratitis caused by herpes virus.
Idebenone
go.drugbank.com/drugs/DB09081ApprovedInvestigationalthe lipid membrane and mitochondria from oxidative damage [A19768]. … It is not currently approved for use by either the Food and Drug Administration (USA) or Health Canada.
Categories: Psychostimulants, Agents Used for ADHD and Nootropics, Compounds used in a research, industrial, or household setting